期刊论文详细信息
Endocrine Journal
Effects of DHMEQ, a Novel Nuclear Factor-κB Inhibitor, on Beta Cell Dysfunction in INS-1 Cells
Chihiro HORIMAI3  Hiroshi HIROSE1  Kazuo UMEZAWA4  Yoshifumi SAISHO1  Izumi TAKEI3  Hiroshi ITOH1  Kiichi MIYASHITA2 
[1] Department of Internal Medicine, Keio University School of Medicine;Institute for Advanced Medical Research, Keio University School of Medicine;Department of Laboratory Medicine, Keio University School of Medicine;Department of Applied Chemistry, Faculty of Science and Technology, Keio University
关键词: Dehydroxymethylepoxyquinomicin;    Nuclear factor-κB;    Tumor necrosis factor-α;    Glucose-stimulated insulin secretion;    Cell viability;    INS-1 cells;   
DOI  :  10.1507/endocrj.K07E-036
学科分类:内分泌与代谢学
来源: Japan Endocrine Society
PDF
【 摘 要 】

References(20)Cited-By(3)Aims: Recent studies suggest that nuclear factor-κB (NF-κB) activation has an important role in leading to beta cell dysfunction in both type 1 and type 2 diabetes. In this study we tested this hypothesis by investigating the effects of dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, on tumor necrosis factor-α (TNF-α)-induced beta cell dysfunction. Methods: INS-1 cells were incubated with TNF- α and with or without DHMEQ for 24 hours. Glucose-stimulated insulin secretion, cell viability, mRNA expression and NF-κB activation were investigated. Results: DHMEQ suppressed TNF-α-induced NF-κB activation and partially ameliorated glucose-stimulated insulin secretion in a dose-dependent manner. DHMEQ also partially ameliorated decreased cell viability and insulin mRNA level induced by TNF-α. Conclusion: DHMEQ suppressed NF-κB activation and ameliorated beta cell dysfunction induced by TNF- α. Inhibition of activated NF-κB in beta cells may be important to ameliorate beta cell dysfunction in diabetes.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201911300770846ZK.pdf 146KB PDF download
  文献评价指标  
  下载次数:30次 浏览次数:7次